25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CytomX Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Cytomx together

I guess you are interested in CytomX Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of CytomX Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about CytomX Therapeutics Inc

I send you an email if I find something interesting about CytomX Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Cytomx (30 sec.)










1.2. What can you expect buying and holding a share of Cytomx? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$-0.37
Expected worth in 1 year
$0.35
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$0.72
Return On Investment
62.7%

For what price can you sell your share?

Current Price per Share
$1.15
Expected price per share
$1.04 - $1.33
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Cytomx (5 min.)




Live pricePrice per Share (EOD)
$1.15
Intrinsic Value Per Share
$-11.10 - $3.19
Total Value Per Share
$-11.47 - $2.82

2.2. Growth of Cytomx (5 min.)




Is Cytomx growing?

Current yearPrevious yearGrowGrow %
How rich?-$31.2m-$57.2m$16.8m41.7%

How much money is Cytomx making?

Current yearPrevious yearGrowGrow %
Making money$2.7m-$12.8m$15.5m562.6%
Net Profit Margin5.4%-738.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Cytomx (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#928 / 960

Most Revenue
#188 / 960

Most Profit
#107 / 960

Most Efficient
#136 / 960
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Cytomx?

Welcome investor! Cytomx's management wants to use your money to grow the business. In return you get a share of Cytomx.

First you should know what it really means to hold a share of Cytomx. And how you can make/lose money.

Speculation

The Price per Share of Cytomx is $1.15. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cytomx.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cytomx, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.37. Based on the TTM, the Book Value Change Per Share is $0.18 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.43 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cytomx.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.08-6.7%0.033.0%-0.28-24.0%-0.19-16.7%-0.22-19.3%
Usd Book Value Change Per Share0.021.3%0.1815.7%-0.43-37.2%-0.08-7.2%-0.01-0.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.2%
Usd Total Gains Per Share0.021.3%0.1815.7%-0.43-37.2%-0.08-7.2%-0.01-0.6%
Usd Price Per Share1.22-1.56-1.57-4.27-8.37-
Price to Earnings Ratio-3.96-11.05--10.39--2.55-8.65-
Price-to-Total Gains Ratio78.70-38.16--14.09-9.23--31.88-
Price to Book Ratio-3.32--3.40--0.11-3.38-8.50-
Price-to-Total Gains Ratio78.70-38.16--14.09-9.23--31.88-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.15
Number of shares869
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.18-0.08
Usd Total Gains Per Share0.18-0.08
Gains per Quarter (869 shares)156.54-72.44
Gains per Year (869 shares)626.16-289.76
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
106266160-290-300
20125212420-580-590
30187818680-869-880
40250524940-1159-1170
50313131200-1449-1460
60375737460-1739-1750
70438343720-2028-2040
80500949980-2318-2330
90563556240-2608-2620
100626262500-2898-2910

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%3.09.00.025.0%4.016.00.020.0%5.035.00.012.5%5.037.01.011.6%
Book Value Change Per Share4.00.00.0100.0%5.07.00.041.7%8.012.00.040.0%13.026.01.032.5%14.026.03.032.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.039.02.5%1.00.042.02.3%
Total Gains per Share4.00.00.0100.0%5.07.00.041.7%8.012.00.040.0%13.026.01.032.5%14.026.03.032.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of CytomX Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0160.180-91%-0.428+2861%-0.083+638%-0.009+160%
Book Value Per Share---0.368-0.498+35%-0.733+99%0.365-201%0.575-164%
Current Ratio--1.0021.176-15%1.583-37%2.514-60%4.428-77%
Debt To Asset Ratio--1.1961.208-1%1.245-4%0.961+24%0.898+33%
Debt To Equity Ratio----0%1.739-100%2.857-100%3.277-100%
Dividend Per Share----0%-0%-0%0.002-100%
Eps---0.0770.034-324%-0.276+258%-0.191+149%-0.222+189%
Free Cash Flow Per Share---0.231-0.264+14%-0.167-28%-0.245+6%-0.121-48%
Free Cash Flow To Equity Per Share---0.171-0.157-9%-0.163-5%-0.141-18%0.039-542%
Gross Profit Margin--1.0060.990+2%1.000+1%0.998+1%0.999+1%
Intrinsic Value_10Y_max--3.192--------
Intrinsic Value_10Y_min---11.102--------
Intrinsic Value_1Y_max---0.367--------
Intrinsic Value_1Y_min---1.163--------
Intrinsic Value_3Y_max---0.578--------
Intrinsic Value_3Y_min---3.472--------
Intrinsic Value_5Y_max---0.159--------
Intrinsic Value_5Y_min---5.737--------
Market Cap89835240.000-15%103554371.040127312354.005-19%122644632.000-16%334612872.801-69%654730966.301-84%
Net Profit Margin---0.2600.054-579%-7.380+2737%-2.284+778%-2.520+869%
Operating Margin---0.337-0.003-99%-8.293+2364%-2.538+654%-2.609+675%
Operating Ratio--1.3371.003+33%9.475-86%3.565-63%5.195-74%
Pb Ratio-3.126+6%-3.316-3.398+2%-0.105-97%3.384-198%8.505-139%
Pe Ratio-3.735+6%-3.96211.050-136%-10.390+162%-2.553-36%8.649-146%
Price Per Share1.150-6%1.2201.560-22%1.570-22%4.270-71%8.374-85%
Price To Free Cash Flow Ratio-1.242+6%-1.318-1.458+11%-4.698+256%-3.354+155%-4.733+259%
Price To Total Gains Ratio74.181-6%78.69638.159+106%-14.093+118%9.234+752%-31.878+141%
Quick Ratio--1.6372.048-20%2.420-32%3.380-52%6.491-75%
Return On Assets---0.0410.013-420%-0.053+29%-0.041-1%-0.054+32%
Return On Equity----0%-0.1990%-0.2030%-0.3320%
Total Gains Per Share--0.0160.180-91%-0.428+2861%-0.083+638%-0.007+146%
Usd Book Value---31227000.000-40398000.000+29%-57235250.000+83%28204100.000-211%44755100.000-170%
Usd Book Value Change Per Share--0.0160.180-91%-0.428+2861%-0.083+638%-0.009+160%
Usd Book Value Per Share---0.368-0.498+35%-0.733+99%0.365-201%0.575-164%
Usd Dividend Per Share----0%-0%-0%0.002-100%
Usd Eps---0.0770.034-324%-0.276+258%-0.191+149%-0.222+189%
Usd Free Cash Flow---19645000.000-21571500.000+10%-13056000.000-34%-19351350.000-1%-9507875.000-52%
Usd Free Cash Flow Per Share---0.231-0.264+14%-0.167-28%-0.245+6%-0.121-48%
Usd Free Cash Flow To Equity Per Share---0.171-0.157-9%-0.163-5%-0.141-18%0.039-542%
Usd Market Cap89835240.000-15%103554371.040127312354.005-19%122644632.000-16%334612872.801-69%654730966.301-84%
Usd Price Per Share1.150-6%1.2201.560-22%1.570-22%4.270-71%8.374-85%
Usd Profit---6534000.0002771500.000-336%-12821500.000+96%-13163950.000+101%-13417900.000+105%
Usd Revenue--25115000.00029892250.000-16%16521000.000+52%20494000.000+23%15150825.000+66%
Usd Total Gains Per Share--0.0160.180-91%-0.428+2861%-0.083+638%-0.007+146%
 EOD+1 -7MRQTTM+11 -21YOY+21 -125Y+19 -1410Y+18 -17

3.3 Fundamental Score

Let's check the fundamental score of CytomX Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.735
Price to Book Ratio (EOD)Between0-1-3.126
Net Profit Margin (MRQ)Greater than0-0.260
Operating Margin (MRQ)Greater than0-0.337
Quick Ratio (MRQ)Greater than11.637
Current Ratio (MRQ)Greater than11.002
Debt to Asset Ratio (MRQ)Less than11.196
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.041
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of CytomX Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.499
Ma 20Greater thanMa 501.210
Ma 50Greater thanMa 1001.237
Ma 100Greater thanMa 2001.397
OpenGreater thanClose1.180
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-09-11 20:17:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Cytomx earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cytomx to the Biotechnology industry mean.
  • A Net Profit Margin of -26.0% means that $-0.26 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of CytomX Therapeutics Inc:

  • The MRQ is -26.0%. The company is making a huge loss. -2
  • The TTM is 5.4%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ-26.0%TTM5.4%-31.4%
TTM5.4%YOY-738.0%+743.5%
TTM5.4%5Y-228.4%+233.8%
5Y-228.4%10Y-252.0%+23.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-26.0%-126.1%+100.1%
TTM5.4%-194.5%+199.9%
YOY-738.0%-207.8%-530.2%
5Y-228.4%-373.2%+144.8%
10Y-252.0%-473.1%+221.1%
4.3.1.2. Return on Assets

Shows how efficient Cytomx is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cytomx to the Biotechnology industry mean.
  • -4.1% Return on Assets means that Cytomx generated $-0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of CytomX Therapeutics Inc:

  • The MRQ is -4.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 1.3%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ-4.1%TTM1.3%-5.4%
TTM1.3%YOY-5.3%+6.6%
TTM1.3%5Y-4.1%+5.3%
5Y-4.1%10Y-5.4%+1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.1%-11.1%+7.0%
TTM1.3%-11.9%+13.2%
YOY-5.3%-11.3%+6.0%
5Y-4.1%-13.2%+9.1%
10Y-5.4%-14.9%+9.5%
4.3.1.3. Return on Equity

Shows how efficient Cytomx is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cytomx to the Biotechnology industry mean.
  • 0.0% Return on Equity means Cytomx generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of CytomX Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-19.9%+19.9%
TTM-5Y-20.3%+20.3%
5Y-20.3%10Y-33.2%+12.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.2%+14.2%
TTM--16.0%+16.0%
YOY-19.9%-13.8%-6.1%
5Y-20.3%-19.1%-1.2%
10Y-33.2%-19.8%-13.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of CytomX Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Cytomx is operating .

  • Measures how much profit Cytomx makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cytomx to the Biotechnology industry mean.
  • An Operating Margin of -33.7% means the company generated $-0.34  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of CytomX Therapeutics Inc:

  • The MRQ is -33.7%. The company is operating very inefficient. -2
  • The TTM is -0.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-33.7%TTM-0.3%-33.3%
TTM-0.3%YOY-829.3%+828.9%
TTM-0.3%5Y-253.8%+253.4%
5Y-253.8%10Y-260.9%+7.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-33.7%-279.4%+245.7%
TTM-0.3%-329.9%+329.6%
YOY-829.3%-230.4%-598.9%
5Y-253.8%-391.8%+138.0%
10Y-260.9%-499.6%+238.7%
4.3.2.2. Operating Ratio

Measures how efficient Cytomx is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.34 means that the operating costs are $1.34 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of CytomX Therapeutics Inc:

  • The MRQ is 1.337. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.003. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.337TTM1.003+0.333
TTM1.003YOY9.475-8.472
TTM1.0035Y3.565-2.561
5Y3.56510Y5.195-1.631
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3372.759-1.422
TTM1.0033.146-2.143
YOY9.4753.336+6.139
5Y3.5655.133-1.568
10Y5.1956.571-1.376
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of CytomX Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Cytomx is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.00 means the company has $1.00 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of CytomX Therapeutics Inc:

  • The MRQ is 1.002. The company is just able to pay all its short-term debts.
  • The TTM is 1.176. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.002TTM1.176-0.174
TTM1.176YOY1.583-0.407
TTM1.1765Y2.514-1.338
5Y2.51410Y4.428-1.915
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0023.806-2.804
TTM1.1764.010-2.834
YOY1.5834.719-3.136
5Y2.5145.980-3.466
10Y4.4286.318-1.890
4.4.3.2. Quick Ratio

Measures if Cytomx is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cytomx to the Biotechnology industry mean.
  • A Quick Ratio of 1.64 means the company can pay off $1.64 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of CytomX Therapeutics Inc:

  • The MRQ is 1.637. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.048. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.637TTM2.048-0.411
TTM2.048YOY2.420-0.372
TTM2.0485Y3.380-1.332
5Y3.38010Y6.491-3.111
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6373.346-1.709
TTM2.0483.567-1.519
YOY2.4204.698-2.278
5Y3.3805.910-2.530
10Y6.4916.500-0.009
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of CytomX Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Cytomx assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cytomx to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.20 means that Cytomx assets are financed with 119.6% credit (debt) and the remaining percentage (100% - 119.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of CytomX Therapeutics Inc:

  • The MRQ is 1.196. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.208. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.196TTM1.208-0.012
TTM1.208YOY1.245-0.037
TTM1.2085Y0.961+0.246
5Y0.96110Y0.898+0.063
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1960.342+0.854
TTM1.2080.344+0.864
YOY1.2450.309+0.936
5Y0.9610.365+0.596
10Y0.8980.384+0.514
4.5.4.2. Debt to Equity Ratio

Measures if Cytomx is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cytomx to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of CytomX Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY1.739-1.739
TTM-5Y2.857-2.857
5Y2.85710Y3.277-0.420
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.393-0.393
TTM-0.439-0.439
YOY1.7390.372+1.367
5Y2.8570.448+2.409
10Y3.2770.489+2.788
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cytomx generates.

  • Above 15 is considered overpriced but always compare Cytomx to the Biotechnology industry mean.
  • A PE ratio of -3.96 means the investor is paying $-3.96 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of CytomX Therapeutics Inc:

  • The EOD is -3.735. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.962. Based on the earnings, the company is expensive. -2
  • The TTM is 11.050. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD-3.735MRQ-3.962+0.227
MRQ-3.962TTM11.050-15.012
TTM11.050YOY-10.390+21.439
TTM11.0505Y-2.553+13.603
5Y-2.55310Y8.649-11.202
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.735-2.310-1.425
MRQ-3.962-2.379-1.583
TTM11.050-2.921+13.971
YOY-10.390-3.405-6.985
5Y-2.553-6.019+3.466
10Y8.649-6.254+14.903
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of CytomX Therapeutics Inc:

  • The EOD is -1.242. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.318. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.458. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.242MRQ-1.318+0.076
MRQ-1.318TTM-1.458+0.140
TTM-1.458YOY-4.698+3.240
TTM-1.4585Y-3.354+1.896
5Y-3.35410Y-4.733+1.379
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.242-2.954+1.712
MRQ-1.318-3.175+1.857
TTM-1.458-3.483+2.025
YOY-4.698-4.594-0.104
5Y-3.354-8.064+4.710
10Y-4.733-8.708+3.975
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Cytomx is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -3.32 means the investor is paying $-3.32 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of CytomX Therapeutics Inc:

  • The EOD is -3.126. Based on the equity, the company is expensive. -2
  • The MRQ is -3.316. Based on the equity, the company is expensive. -2
  • The TTM is -3.398. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.126MRQ-3.316+0.190
MRQ-3.316TTM-3.398+0.082
TTM-3.398YOY-0.105-3.293
TTM-3.3985Y3.384-6.783
5Y3.38410Y8.505-5.120
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.1261.886-5.012
MRQ-3.3161.972-5.288
TTM-3.3982.201-5.599
YOY-0.1052.363-2.468
5Y3.3843.551-0.167
10Y8.5054.200+4.305
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of CytomX Therapeutics Inc.

4.8.1. Institutions holding CytomX Therapeutics Inc

Institutions are holding 72.261% of the shares of CytomX Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30TANG CAPITAL MANAGEMENT LLC9.97460.96827791936134193620.8052
2024-06-30HHG PLC8.06730.0041630198363019830
2024-06-30Bvf Inc6.69310.17885228461-1367340-20.7305
2024-06-30Vanguard Group Inc6.26270.00014892302349280.7191
2024-06-30Adage Capital Partners Gp LLC3.84040.00683000000100000050
2024-03-31Acadian Asset Management LLC3.44460.02042690830446401.687
2024-06-30Millennium Management LLC2.36230.00118454031173775174.7656
2024-06-30LAURION CAPITAL MANAGEMENT LP1.9540.022152638776220099.74
2024-06-30Jacobs Levy Equity Management, Inc.1.93010.00761507717977782184.5098
2024-06-30Schonfeld Strategic Advisors LLC1.76050.010813752901007837.9076
2024-06-30Assenagon Asset Management SA1.58540.00341238499833825206.0486
2024-06-30RTW INVESTMENTS, LLC1.53610.0227120000212000020
2024-06-30Renaissance Technologies Corp1.51440.00251183022-49778-4.0378
2024-06-30Congress Park Capital LLC1.47630.56511153220919420393.2506
2024-06-30SUPERSTRING CAPITAL MANAGEMENT LP1.47411.7709115151847211569.4897
2024-06-30BlackRock Inc1.45810113902978210.6914
2024-03-31Morgan Stanley - Brokerage Accounts1.09580.0002855984777063984.6087
2024-06-30Geode Capital Management, LLC0.98510.0001769499161012.1371
2024-06-30Two Sigma Investments LLC0.84740.0018661947408174160.8422
2024-06-30ADAR1 Capital Management LLC0.73240.1318572170417170269.1419
Total 58.99473.718346085199+15372600+33.4%

4.9.2. Funds holding CytomX Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-07-31Vanguard Total Stock Mkt Idx Inv2.86910.00022241253557912.5528
2024-07-31Vanguard Institutional Extnd Mkt Idx Tr1.25640.001398149100
2024-06-30Vanguard Explorer Inv1.05030.004682046100
2024-06-30Vanguard Strategic Small-Cap Equity Inv0.71060.043155511900
2024-07-31Fidelity Extended Market Index0.58480.0015456835100922.259
2024-06-30Acadian Global Small-Cap Equity CIT Cl A0.48990.13563827233827230
2024-08-30Formidable ETF0.31491.239924600100
2024-06-30Vanguard VIF Small Co Gr0.30190.019423581400
2024-06-30Candriam Global Equities Oncology0.26880.01452100002100000
2024-06-30Bridgeway Ultra-Small Company Market0.24130.137118850000
2024-06-30Bridgeway Ultra-Small Company0.23120.2828180624-74100-29.0903
2024-08-30Fidelity Enhanced Small Cap ETF0.21870.022317083600
2024-06-30BlackRock Extended Equity Market K0.20250.0014158158-152-0.096
2024-08-30iShares Micro-Cap ETF0.20080.020315686800
2024-07-31Fidelity Total Market Index0.15210.0002118852-158-0.1328
2024-06-30Fidelity VIP Disciplined Small Cap Init0.13870.034210831100
2024-07-31Fidelity Series Total Market Index0.12080.00029439300
2024-06-30Northern Trust Extended Eq Market Idx0.08470.00126615100
2024-06-30NT Ext Equity Mkt Idx Fd - L0.08470.00126615100
2024-06-30NT Ext Equity Mkt Idx Fd - NL0.07550.00115898200
Total 9.59771.96217497523+584196+7.8%

5.3. Insider Transactions

Insiders are holding 1.004% of the shares of CytomX Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-08-20Christopher OgdenSELL19841.23
2024-08-20Jeffrey B LandauSELL41811.23
2024-08-20Sean A MccarthySELL138981.23
2024-03-19Christopher OgdenSELL29712.09
2024-03-19Jeffrey B LandauSELL65622.09
2024-03-19Lloyd A RowlandSELL52682.09
2024-03-19Sean A MccarthySELL202232.09
2023-12-20Marcia BelvinSELL40771.38
2023-12-20Sean A MccarthySELL135511.38
2023-09-22Lloyd A RowlandSELL54861.3
2023-09-22Marcia BelvinSELL41191.3
2023-09-22Sean A MccarthySELL146011.3
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets159,219
Total Liabilities190,446
Total Stockholder Equity-31,227
 As reported
Total Liabilities 190,446
Total Stockholder Equity+ -31,227
Total Assets = 159,219

Assets

Total Assets159,219
Total Current Assets143,080
Long-term Assets16,139
Total Current Assets
Cash And Cash Equivalents 43,247
Short-term Investments 93,935
Net Receivables 2,775
Other Current Assets 3,123
Total Current Assets  (as reported)143,080
Total Current Assets  (calculated)143,080
+/-0
Long-term Assets
Property Plant Equipment 13,541
Goodwill 949
Intangible Assets 656
Long-term Assets Other 76
Long-term Assets  (as reported)16,139
Long-term Assets  (calculated)15,222
+/- 917

Liabilities & Shareholders' Equity

Total Current Liabilities142,858
Long-term Liabilities47,588
Total Stockholder Equity-31,227
Total Current Liabilities
Short-term Debt 4,861
Accounts payable 611
Other Current Liabilities 13,620
Total Current Liabilities  (as reported)142,858
Total Current Liabilities  (calculated)19,092
+/- 123,766
Long-term Liabilities
Capital Lease Obligations 11,746
Long-term Liabilities Other 3,993
Long-term Liabilities  (as reported)47,588
Long-term Liabilities  (calculated)15,739
+/- 31,849
Total Stockholder Equity
Common Stock1
Retained Earnings -716,191
Accumulated Other Comprehensive Income -4
Other Stockholders Equity 684,967
Total Stockholder Equity (as reported)-31,227
Total Stockholder Equity (calculated)-31,227
+/-0
Other
Capital Stock1
Cash and Short Term Investments 137,182
Common Stock Shares Outstanding 84,881
Current Deferred Revenue123,766
Liabilities and Stockholders Equity 159,219
Net Debt -31,501
Net Invested Capital -31,227
Net Working Capital 222
Property Plant and Equipment Gross 13,541
Short Long Term Debt Total 11,746



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-31
> Total Assets 
14,183
0
0
0
73,062
67,242
134,089
124,779
197,215
191,952
206,860
192,881
199,128
177,882
351,855
387,039
397,644
376,462
376,942
482,726
457,108
444,513
405,284
372,544
341,282
436,662
402,479
375,182
358,663
434,158
402,440
371,233
339,411
296,825
260,086
226,492
260,891
234,630
209,185
221,167
205,151
184,687
159,219
159,219184,687205,151221,167209,185234,630260,891226,492260,086296,825339,411371,233402,440434,158358,663375,182402,479436,662341,282372,544405,284444,513457,108482,726376,942376,462397,644387,039351,855177,882199,128192,881206,860191,952197,215124,779134,08967,24273,06200014,183
   > Total Current Assets 
0
8,703
0
0
66,853
60,673
127,258
115,070
189,754
184,548
199,606
183,313
188,147
166,909
340,680
376,374
388,601
367,031
366,671
472,508
445,475
405,077
366,677
334,778
303,335
400,066
366,566
340,305
324,013
400,008
271,005
240,998
310,301
268,444
232,770
200,280
237,102
212,277
187,801
201,204
182,936
167,247
143,080
143,080167,247182,936201,204187,801212,277237,102200,280232,770268,444310,301240,998271,005400,008324,013340,305366,566400,066303,335334,778366,677405,077445,475472,508366,671367,031388,601376,374340,680166,909188,147183,313199,606184,548189,754115,070127,25860,67366,853008,7030
       Cash And Cash Equivalents 
8,703
-8,703
0
0
64,396
7,819
45,842
36,191
59,822
67,897
62,379
59,758
104,645
85,662
272,860
284,225
177,548
142,155
132,908
259,753
247,577
190,407
149,392
164,646
188,425
143,286
291,388
176,810
191,859
329,666
256,146
236,284
205,530
163,488
129,290
95,036
193,650
56,357
57,536
26,024
17,171
36,185
43,247
43,24736,18517,17126,02457,53656,357193,65095,036129,290163,488205,530236,284256,146329,666191,859176,810291,388143,286188,425164,646149,392190,407247,577259,753132,908142,155177,548284,225272,86085,662104,64559,75862,37967,89759,82236,19145,8427,81964,39600-8,7038,703
       Short-term Investments 
100
17,406
0
0
100
51,654
79,527
77,495
126,889
112,739
133,418
118,707
77,293
76,861
63,056
47,050
196,562
219,321
202,238
204,809
188,550
206,189
199,750
161,067
107,720
104,636
55,013
144,266
124,260
64,130
10,031
5
99,696
99,042
98,875
99,254
99,696
148,145
123,322
168,086
157,338
114,099
93,935
93,935114,099157,338168,086123,322148,14599,69699,25498,87599,04299,696510,03164,130124,260144,26655,013104,636107,720161,067199,750206,189188,550204,809202,238219,321196,56247,05063,05676,86177,293118,707133,418112,739126,88977,49579,52751,6541000017,406100
       Net Receivables 
0
0
0
0
1,875
210
631
406
744
474
398
447
2,313
268
185
40,251
10,139
81
25,137
56
97
44
10,004
7
13
143,071
13,267
13,604
798
756
931
887
790
1,016
1,014
1,712
35,986
1,090
1,903
2,419
3,432
13,177
2,775
2,77513,1773,4322,4191,9031,09035,9861,7121,0141,01679088793175679813,60413,267143,07113710,00444975625,1378110,13940,2511852682,3134473984747444066312101,8750000
       Inventory 
0
0
0
0
100
0
100
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000010010001000000
   > Long-term Assets 
0
-8,703
0
0
6,209
6,569
6,831
9,709
7,461
7,404
7,254
9,568
10,981
10,973
11,175
10,665
9,043
9,431
10,271
10,218
11,633
39,436
38,607
37,766
37,947
36,596
35,913
34,877
34,650
34,150
131,435
130,235
29,110
28,381
27,316
26,212
23,789
22,353
21,384
19,963
22,215
17,440
16,139
16,13917,44022,21519,96321,38422,35323,78926,21227,31628,38129,110130,235131,43534,15034,65034,87735,91336,59637,94737,76638,60739,43611,63310,21810,2719,4319,04310,66511,17510,97310,9819,5687,2547,4047,4619,7096,8316,5696,20900-8,7030
       Property Plant Equipment 
2,070
0
0
0
3,018
3,400
3,499
3,667
3,481
3,479
3,370
3,701
4,392
4,604
4,319
4,087
4,218
4,622
5,499
5,482
6,934
34,773
33,981
33,176
32,754
32,075
31,428
30,429
29,445
28,908
27,660
26,441
25,322
24,629
23,607
22,540
21,021
19,621
18,625
17,244
16,178
14,801
13,541
13,54114,80116,17817,24418,62519,62121,02122,54023,60724,62925,32226,44127,66028,90829,44530,42931,42832,07532,75433,17633,98134,7736,9345,4825,4994,6224,2184,0874,3194,6044,3923,7013,3703,4793,4813,6673,4993,4003,0180002,070
       Goodwill 
949
0
0
0
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949
949949949949949949949949949949949949949949949949949949949949949949949949949949949949949949949949949949949949949949949000949
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
2,025
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
99,914
99,969
0
0
0
0
0
0
0
0
0
0
0
0000000000099,96999,9140000000000000000002,02500000000000
       Intangible Assets 
2,699
0
0
0
1,750
1,750
1,750
1,750
1,750
1,750
1,750
1,750
1,750
1,750
1,750
1,641
1,604
1,568
1,531
1,495
1,458
1,422
1,385
1,349
1,312
1,276
1,240
1,203
1,167
1,130
1,094
1,057
1,021
984
948
911
875
839
802
766
729
693
656
6566937297668028398759119489841,0211,0571,0941,1301,1671,2031,2401,2761,3121,3491,3851,4221,4581,4951,5311,5681,6041,6411,7501,7501,7501,7501,7501,7501,7501,7501,7501,7501,7500002,699
       Long-term Assets Other 
0
-8,703
0
0
492
470
633
3,343
1,281
1,226
1,185
1,143
3,890
3,670
4,157
3,988
2,272
2,292
2,292
2,292
2,292
2,292
2,292
2,292
2,932
2,296
2,296
2,296
3,089
2,246
1,818
1,819
-3,709
902
1,812
1,812
-3,568
944
1,008
1,004
83
80
76
7680831,0041,008944-3,5681,8121,812902-3,7091,8191,8182,2463,0892,2962,2962,2962,9322,2922,2922,2922,2922,2922,2922,2922,2723,9884,1573,6703,8901,1431,1851,2261,2813,34363347049200-8,7030
> Total Liabilities 
13,744
0
0
0
151,603
73,238
70,486
230,827
71,147
79,238
105,673
103,459
120,649
104,095
299,618
341,560
327,748
326,815
335,809
325,065
326,225
321,942
303,783
290,435
290,169
366,895
343,650
327,118
308,860
288,136
271,487
259,559
250,032
228,631
211,378
198,018
346,642
321,267
294,212
272,405
252,598
216,367
190,446
190,446216,367252,598272,405294,212321,267346,642198,018211,378228,631250,032259,559271,487288,136308,860327,118343,650366,895290,169290,435303,783321,942326,225325,065335,809326,815327,748341,560299,618104,095120,649103,459105,67379,23871,147230,82770,48673,238151,60300013,744
   > Total Current Liabilities 
4,172
0
0
0
11,163
10,489
10,938
13,973
15,739
17,003
22,224
23,682
35,767
37,126
60,635
71,241
61,147
69,707
83,212
86,274
97,908
96,217
78,673
76,126
85,590
106,001
98,785
102,033
100,924
98,049
93,377
99,772
106,316
102,766
99,439
97,841
152,608
151,262
141,377
146,790
155,913
144,536
142,858
142,858144,536155,913146,790141,377151,262152,60897,84199,439102,766106,31699,77293,37798,049100,924102,03398,785106,00185,59076,12678,67396,21797,90886,27483,21269,70761,14771,24160,63537,12635,76723,68222,22417,00315,73913,97310,93810,48911,1630004,172
       Short-term Debt 
0
0
0
0
1,419
1,360
1,245
0
0
0
0
0
0
0
0
0
0
1,035
2,692
4,990
13,339
2,544
2,631
2,719
2,810
2,903
2,998
3,096
3,195
3,297
3,402
3,509
3,618
3,730
3,845
3,961
4,082
4,204
4,330
4,458
4,589
4,724
4,861
4,8614,7244,5894,4584,3304,2044,0823,9613,8453,7303,6183,5093,4023,2973,1953,0962,9982,9032,8102,7192,6312,54413,3394,9902,6921,03500000000001,2451,3601,4190000
       Short Long Term Debt 
0
0
0
0
1,419
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,544
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000002,54400000000000000001,4190000
       Accounts payable 
930
0
0
0
1,919
1,486
760
2,700
4,697
4,958
1,426
517
6,596
3,700
6,364
2,869
4,205
5,349
4,240
6,871
5,132
9,511
4,520
4,550
4,158
3,782
4,927
3,643
2,996
2,582
1,755
1,516
2,818
1,721
1,920
5,176
2,809
2,203
1,029
1,705
1,458
1,964
611
6111,9641,4581,7051,0292,2032,8095,1761,9201,7212,8181,5161,7552,5822,9963,6434,9273,7824,1584,5504,5209,5115,1326,8714,2405,3494,2052,8696,3643,7006,5965171,4264,9584,6972,7007601,4861,919000930
       Other Current Liabilities 
1,984
0
0
0
1,695
7,643
2,803
5,143
4,912
4,738
7,313
9,041
8,824
6,336
7,499
11,444
16,383
16,335
24,768
21,416
26,724
33,397
19,838
17,777
27,241
25,450
18,149
20,849
19,864
15,534
15,851
21,658
30,618
27,302
27,887
27,379
24,450
18,071
15,738
16,231
17,599
14,220
13,620
13,62014,22017,59916,23115,73818,07124,45027,37927,88727,30230,61821,65815,85115,53419,86420,84918,14925,45027,24117,77719,83833,39726,72421,41624,76816,33516,38311,4447,4996,3368,8249,0417,3134,7384,9125,1432,8037,6431,6950001,984
   > Long-term Liabilities 
0
0
0
0
140,440
62,749
59,548
216,854
55,408
62,235
83,449
79,777
84,882
66,969
238,983
270,319
266,601
257,108
252,597
238,791
228,317
225,725
225,110
214,309
204,579
260,894
244,865
225,085
207,936
190,087
178,110
159,787
143,716
125,865
111,939
100,177
194,034
170,005
152,835
125,615
96,685
71,831
47,588
47,58871,83196,685125,615152,835170,005194,034100,177111,939125,865143,716159,787178,110190,087207,936225,085244,865260,894204,579214,309225,110225,725228,317238,791252,597257,108266,601270,319238,98366,96984,88279,77783,44962,23555,408216,85459,54862,749140,4400000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-1,419
-1,360
-1,245
0
0
0
0
0
0
0
0
0
0
-1,035
-2,692
-4,990
-13,339
27,008
26,321
25,621
24,871
24,105
23,323
22,525
21,675
20,807
19,921
19,017
18,056
17,077
16,076
15,055
13,975
12,872
11,746
10,597
9,385
8,148
6,885
6,8858,1489,38510,59711,74612,87213,97515,05516,07617,07718,05619,01719,92120,80721,67522,52523,32324,10524,87125,62126,32127,008-13,339-4,990-2,692-1,0350000000000-1,245-1,360-1,4190000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
1,032
0
0
153
154
566
978
1,391
1,803
1,897
2,055
2,281
238,791
228,317
963
963
963
850
260,894
244,865
225,085
207,936
190,087
178,110
159,787
143,716
125,865
111,939
100,177
262,000
170,005
152,835
2,757
3,893
3,940
3,993
3,9933,9403,8932,757152,835170,005262,000100,177111,939125,865143,716159,787178,110190,087207,936225,085244,865260,894850963963963228,317238,7912,2812,0551,8971,8031,391978566154153001,0320000000
       Deferred Long Term Liability 
0
0
0
0
61,332
0
0
56,743
54,703
62,235
83,296
79,623
84,316
65,991
237,592
268,516
264,704
255,053
250,316
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000250,316255,053264,704268,516237,59265,99184,31679,62383,29662,23554,70356,7430061,3320000
> Total Stockholder Equity
439
583
0
0
-78,541
-5,996
63,603
-106,048
126,068
112,714
101,187
89,422
78,479
73,787
52,237
45,479
69,896
49,647
41,133
157,661
130,883
122,571
101,501
82,109
51,113
69,767
58,829
48,064
49,803
146,022
130,953
111,674
89,379
68,194
48,708
28,474
-85,751
-86,637
-85,027
-51,238
-47,447
-31,680
-31,227
-31,227-31,680-47,447-51,238-85,027-86,637-85,75128,47448,70868,19489,379111,674130,953146,02249,80348,06458,82969,76751,11382,109101,501122,571130,883157,66141,13349,64769,89645,47952,23773,78778,47989,422101,187112,714126,068-106,04863,603-5,996-78,54100583439
   Common Stock
1
0
0
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1111111111111111111111111111111111111110001
   Retained Earnings Total Equity0000-727,277-726,190-623,562-605,089-581,793-557,609-533,724-507,496-484,912-465,669-450,115-435,414-420,704-405,025-417,230-381,775-358,076-329,116-314,981-282,748-259,317-245,870-219,465-220,086-209,839-184,623-176,366-162,333-147,671-133,4950-105,9790000000
   Accumulated Other Comprehensive Income 
0
-44,279
0
0
-404
-416
-1
8
-76
30
80
6
-27
-100
-110
-61
-94
-228
-178
-208
-93
73
209
110
57
336
16
-47
-47
-43
15
52
-242
-919
-1,162
-795
10
26
35
-63
95
-10
-4
-4-1095-63352610-795-1,162-919-2425215-43-47-47163365711020973-93-208-178-228-94-61-110-100-2768030-768-1-416-40400-44,2790
   Capital Surplus 
0
0
0
0
0
0
0
0
0
246,256
248,777
251,748
254,871
258,509
262,185
265,625
289,454
295,744
300,627
440,616
445,956
451,613
459,367
463,773
468,285
474,455
479,516
483,524
499,964
611,733
615,849
619,117
623,344
626,721
631,662
634,357
623,344
639,526
642,214
0
0
0
0
0000642,214639,526623,344634,357631,662626,721623,344619,117615,849611,733499,964483,524479,516474,455468,285463,773459,367451,613445,956440,616300,627295,744289,454265,625262,185258,509254,871251,748248,777246,256000000000
   Treasury Stock0000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
-76,896
0
-407
-866
243,609
246,178
248,777
251,748
254,871
258,509
262,185
265,625
289,454
295,744
300,627
440,616
445,956
451,613
459,367
463,773
468,285
474,455
479,516
483,524
499,964
611,733
615,849
619,117
623,344
626,721
631,662
634,357
637,117
639,526
642,214
673,109
675,905
677,986
684,967
684,967677,986675,905673,109642,214639,526637,117634,357631,662626,721623,344619,117615,849611,733499,964483,524479,516474,455468,285463,773459,367451,613445,956440,616300,627295,744289,454265,625262,185258,509254,871251,748248,777246,178243,609-866-4070-76,8960000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue101,214
Cost of Revenue-2,175
Gross Profit99,03999,039
 
Operating Income (+$)
Gross Profit99,039
Operating Expense-105,523
Operating Income-6,484-6,484
 
Operating Expense (+$)
Research Development75,651
Selling General Administrative30,018
Selling And Marketing Expenses146
Operating Expense105,523105,815
 
Net Interest Income (+$)
Interest Income8,066
Interest Expense-0
Other Finance Cost-0
Net Interest Income8,066
 
Pretax Income (+$)
Operating Income-6,484
Net Interest Income8,066
Other Non-Operating Income Expenses0
Income Before Tax (EBT)3,323-16,291
EBIT - interestExpense = -6,484
3,323
-569
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-6,4843,323
Earnings Before Interest and Taxes (EBITDA)-4,309
 
After tax Income (+$)
Income Before Tax3,323
Tax Provision-2,823
Net Income From Continuing Ops-10,181500
Net Income-569
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses107,698
Total Other Income/Expenses Net9,807-8,066
 

Technical Analysis of Cytomx
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cytomx. The general trend of Cytomx is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cytomx's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of CytomX Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.32 < 1.33 < 1.33.

The bearish price targets are: 1.1101 > 1.09 > 1.04.

Tweet this
CytomX Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of CytomX Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

CytomX Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of CytomX Therapeutics Inc. The current macd is -0.0181534.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cytomx price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cytomx. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cytomx price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
CytomX Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartCytomX Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of CytomX Therapeutics Inc. The current adx is 13.87.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cytomx shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
CytomX Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of CytomX Therapeutics Inc. The current sar is 1.2724878.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
CytomX Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of CytomX Therapeutics Inc. The current rsi is 42.50. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
CytomX Therapeutics Inc Daily Relative Strength Index (RSI) ChartCytomX Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of CytomX Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cytomx price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
CytomX Therapeutics Inc Daily Stochastic Oscillator ChartCytomX Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of CytomX Therapeutics Inc. The current cci is -116.37655812.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
CytomX Therapeutics Inc Daily Commodity Channel Index (CCI) ChartCytomX Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of CytomX Therapeutics Inc. The current cmo is -20.36757198.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
CytomX Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartCytomX Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of CytomX Therapeutics Inc. The current willr is -78.98894155.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cytomx is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
CytomX Therapeutics Inc Daily Williams %R ChartCytomX Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of CytomX Therapeutics Inc.

CytomX Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of CytomX Therapeutics Inc. The current atr is 0.0726194.

CytomX Therapeutics Inc Daily Average True Range (ATR) ChartCytomX Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of CytomX Therapeutics Inc. The current obv is 258,457,657.

CytomX Therapeutics Inc Daily On-Balance Volume (OBV) ChartCytomX Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of CytomX Therapeutics Inc. The current mfi is 41.62.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
CytomX Therapeutics Inc Daily Money Flow Index (MFI) ChartCytomX Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for CytomX Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-05-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-21MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-05-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-05-30MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-05-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-06-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-06-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-06-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-14STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-18STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-06-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-02MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-07STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-10WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

CytomX Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of CytomX Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.499
Ma 20Greater thanMa 501.210
Ma 50Greater thanMa 1001.237
Ma 100Greater thanMa 2001.397
OpenGreater thanClose1.180
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Cytomx with someone you think should read this too:
  • Are you bullish or bearish on Cytomx? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cytomx? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about CytomX Therapeutics Inc

I send you an email if I find something interesting about CytomX Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about CytomX Therapeutics Inc.

Receive notifications about CytomX Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.